Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRISTOL-MYERS SQUIBB LOOKING UPSA INTO EUROPEAN OTC BUSINESS

Executive Summary

BRISTOL-MYERS SQUIBB LOOKING UPSA INTO EUROPEAN OTC BUSINESS with the acquisition of a large minority stake in UPSA Group. UPSA is described by Bristol as the largest privately held European OTC drug firm and a leader in the effervescent products technology. Under the agreement, announced Aug. 31, BMS will acquire 33.56% of the UPSA Investments holding company and a "significant minority interest" in UPSA Group. The "alliance will play a central role" in BMS' plans to expand its small position in the European OTC market, the company said. UPSA, established some 55 years ago, had 1989 sales of over$200 mil., according to industry sources. The company markets a broad line of effervescent OTC products, including analgesics, (Efferalgan, Dafalgan and Aspirine UPSA brands) cough/cold medicines, anti-inflammatories and vitamins, and the prescription anti-arrhythmic Cipralan (cibenzoline). UPSA's OTC analgesics rank second in Europe in market share behind Bayer AG and industry estimates put UPSA's share of the French pain relief market at around 30%, with control of approximately half of the French acetaminophen market. UPSA products also have "strong positions" in Belgium and Spain and a "growing presence" in Italy, BMS said. BMS plans to expand UPSA's effervescent product lines on a worldwide basis, particularly to the U.S. and Japan. While UPSA's technology could theoretically be used to create new formulations of BMS' own brands, such as Bufferin, Excedrin analgesics and Comtrex cold medicine, the U.S. market for effervescent products has yet to catch fire. Bristol-Myers Squibb currently does not have any effervescent products. Financial terms of the agreement, which are subject to approval by the French Ministry of Industry, were not disclosed. BMS also has the option to acquire, "in the longer term," the remaining UPSA stock, also subject to French government approval. UPSA management will remain in place; however, a new board of directors will be formed in which BMS will control three seats out of seven. UPSA Group is led by president, CEO and majority stockholder Nicole Bru, MD. Formerly the head of UPSA R&D, she took the helm of the firm after the death of her husband Jean Bru, MD. UPSA, which has its manufacturing headquarters in Agen, France, also has an R&D facility in Rueil-Malmaison. The company employs about 1,200 employees with a sales force at just over 275. The company currently does not have a presence in the U.S.
UsernamePublicRestriction

Register

PS017994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel